SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017)
Clin. transl. oncol. (Print)
; 20(1): 22-28, ene. 2018. tab, ilus
Artigo
em Inglês
| IBECS
| ID: ibc-170464
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Glioblastoma (GB) is the most common brain malignancy and accounts for over 50% of all high-grade gliomas. Radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ) chemotherapy is the current standard of care for patients with newly diagnosed GB up to age 70. Recently, a new standard of care has been adopted for elderly patients (≥ 65 years) based on short course of RT and TMZ. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent GB is not well defined, and decision-making is usually based on prior strategies as well as several clinical and radiological factors. The presence of neurologic deficits and seizures can significantly impact quality of life (AU9
RESUMEN
No disponible
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Glioblastoma
Tipo de estudo:
Estudo diagnóstico
/
Guia de prática clínica
/
Estudo prognóstico
Aspecto:
Preferência do paciente
Limite:
Humanos
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2018
Tipo de documento:
Artigo
Instituição/País de afiliação:
Complejo Hospitalario Universitario de Granada Virgen de las Nieves/Spain
/
Complejo Hospitalario de Navarra/Spain
/
Hospital Ramón y Cajal/Spain
/
Hospital Ruber Internacional/Spain
/
Hospital Universitari Germans Trias i Pujol de Badalona/Spain
/
Hospital Universitari Vall dHebron/Spain
/
Hospital Universitario de Salamanca/Spain
/
Institut Català dOncologia (ICO)/Spain
/
Parc de Salut Mar/Spain
